2026

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis
Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, Harzer M, Kamili A, Bartke L, Cords L, Vorwerk J, Leitner T, Maulhardt M, Brinkert K, Brioli A, Richardson T, Holtick U, Hillmann S, Salwender H, Khandanpour C, Bokemeyer C, Weisel K, Kosch R
AM J HEMATOL. 2026 [Epub ahead of print].

Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Frenking J, Riedhammer C, Hielscher T, Schaefers C, Leypoldt L, Harzer M, Sedloev D, Landrin V, Kehl N, Friedrich M, Zhou X, Steinhardt M, Weis P, Mersi J, Waldschmidt J, Weinhold N, Kortüm K, Müller-Tidow C, Einsele H, Sauer S, Weisel K, Richardson T, Teipel R, Rasche L, Raab M
BLOOD CANCER DISCOV. 2026.

2025

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):126.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):.

Letzte Aktualisierung aus dem FIS: 19.04.2026 - 05:18 Uhr